AI-generated · cited to primary sources · not investment advice
Alkem Lab (539523) Jun 2026 Filing Analysis
Does management do what it says?
US sales grew by 28.0% YoY in Q2 FY26, far exceeding the mid-single-digit guidance, driven by new launches like Sacubitril/Valsartan and CDMO business. (1 exceeded across 1 tracked commitment)
“So, our expected launch is around September or October, somewhere around that time.”
Management confirmed they are outperforming the IPM in six core therapies, with growth rates significantly higher than the market (e.g., 1.4x in anti-infectives, 2x in vitamins). (1 met across 1 tracked commitment)
“We are close to 22% of our business is from chronic and which is if you see our last 3- or 4-years trend, every year, we are improving it internally by at least 1%.”
Management expects to file for Denosumab (Prolia/Xgevia) biosimilars in the U.S. market in approximately 1.5 years. — target: 1.5 years (+4 more commitments)
“So, we will start our filing even for the U.S. market, maybe in 1.5 years, we will file for U.S.”
See the full cited Management analysis of Alkem Lab
How durable is the business?
Alkem is successfully outperforming the market in chronic and sub-chronic therapy areas like Anti-Diabetics and Neuro/CNS, strengthening its brand moat. (1 expanding)
“our chronic business as far as branded generic business is concerned. We are close to 22% of our business is from chronic and which is if you see our last 3- or 4-years trend, every year, we are improving it internally by at least 1%.”
The domestic business continues to expand, outperforming the Indian Pharmaceutical Market (IPM) by 100-150 basis points. Alkem has achieved the #1 rank in the Acute segment and #2 in new product launches. (2 expanding, 1 stable)
“our number of MRs at a group level is around 14,500... We are at 18% to 19% kind of attrition currently and which has been a substantial reduction from the previous years and much lower than the industry average”
The domestic business continues to expand, outperforming the Indian Pharmaceutical Market (IPM) growth of 8.5% with a 9.7% growth rate, driven by strong volume growth. (5 expanding across 1 engine)
“In Q4, our total revenue from operations was INR36,033 million... India sales were INR23,245 million with a Y-o-Y growth of 8.8%.”
International revenue grew 8.9% overall (U.S. at 8.8% and Non-U.S. at 9.1%), showing steady growth but slower than the previous 25.4% YoY pace. (5 expanding across 1 engine)
“international sales were INR12,223 million with a Y-o-Y growth of 25.4%.”
See the full cited Business Model analysis of Alkem Lab
Where does growth come from?
Alkem is aggressively entering the high-growth anti-diabetic space with new launches like Semaglutide and Tirzepatide, growing this segment 2x faster than the market when excluding these new molecules. (1 new trend, 2 accelerating across 3 signals)
“a key highlight has been the successful day 1 launch of semaglutide in the month of March 2026... we could garner a market -- unit market share of around 11% and we expect it to go up even further in the coming months.”
While total international sales saw a full-year decline, the 'Other International' (Non-US) segment is accelerating sharply, growing 28.2% in the final quarter compared to 8.7% for the full year. (5 accelerating across 5 signals)
“International sales were INR4,610 million with a Y-o-Y growth of 22.5%.”
The company is showing accelerating growth in chronic-heavy therapies like Anti-Diabetic (12.0%) and Respiratory (16.7%), significantly outperforming market growth rates in these segments. (3 accelerating, 1 new trend, 1 steady across 5 signals)
“chronic segment reported 16.1% versus the IPM growth of 13.6%, which is almost a 250-basis point outperformance.”
The CDMO initiative through Enzene is in its early stages. The U.S. facility is expected to be fully operational by Q4 FY26, with an estimated quarterly opex of INR 50 crores. Revenue is currently marginal but expected to scale significantly once the facility is operational. (4 new trend across 4 signals)
“Last year, we recognized some CDMO from U.S. that was like less than INR100 crores... It would take time for us to get like meaningfully like INR200 crores, INR300 crores. It will take us a couple of years.”
Alkem is building a robust MedTech platform that functions similarly to a CDMO/Specialty play, acquiring Occlutech to gain a 'ready-to-use' global distribution and R&D platform. This move shifts the company from simple manufacturing to high-barrier, patented medical technology. (2 new trend across 2 signals, 1 leading indicator)
“Our clinical trial for tablets is on. We will be going to the regulator in a while and once we get the approval from the innovator, we'll figure out the go-to-market strategy”
See the full cited Future Growth analysis of Alkem Lab
What could break the thesis?
The company is subject to government price controls in India, which limits its ability to raise prices to offset rising costs. [REGULATORY]
“What pricing risk we do to mitigate, I think nobody in the world can do that because the pricing is going by regulations which we have to follow.”
The risk is easing as the company reported a positive impact of 0.8% to 0.9% on gross margins due to lower API prices. (1 easing, 2 intensifying, 1 high-severity)
“the current geopolitical environment and evolving global supply chain dynamics have resulted in increased logistics costs along with some pressure on APIs and the packaging materials.”
EASING. US sales grew significantly by 28.0% YoY, driven by high-value launches like Sacubitril/Valsartan and CDMO business. The company also filed 2 ANDAs and launched 4 products this quarter to offset erosion. (1 easing, 4 stable, 1 high-severity)
“What happens is on the base business, U.S. as a market is a value erosion that we see over a period of time.”
The risk is intensifying in the short term as the company expects losses of INR 40-50 crores per year for FY26 and FY27 before breaking even in FY28. (3 intensifying, 2 easing)
“And I would like to place on record that Dr. Vikas is going to now kind of proceed from Alkem and he's done a fantastic job, and he will be missed.”
STABLE. While the document does not provide specific profit/loss for Enzene, the company continues to invest, filing its first BLA (Biologics License Application) in Q1FY26, indicating the facility is operational but still in the high-spend phase. (2 stable, 1 easing)
“So, the pricing pressures for everyone, we'll figure it out how it settles.”
See the full cited Risk analysis of Alkem Lab
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.